These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30529990)

  • 1. Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
    Yap KK; Wong W; Ji L; Groshen S; Quinn DI; Bryce AH; Dorff TB
    Cancer Treat Res Commun; 2019; 18():100114. PubMed ID: 30529990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
    Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
    Saad F; Sternberg CN; Mulders PFA; Niepel D; Tombal BF
    Cancer Treat Rev; 2018 Jul; 68():25-37. PubMed ID: 29787892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
    Becker DJ; Iyengar AD; Punekar SR; Ng J; Zaman A; Loeb S; Becker KD; Makarov D
    Anticancer Res; 2019 May; 39(5):2467-2473. PubMed ID: 31092441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Nilsson S
    Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
    Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
    Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
    Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
    Zhao H; Howard LE; De Hoedt AM; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
    Prostate; 2021 May; 81(7):390-397. PubMed ID: 33705584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
    Sasaki D; Hatakeyama S; Kawaguchi H; Hatayama Y; Ishibashi Y; Kusaka A; Noro D; Tanaka T; Ito H; Okuyama Y; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Aoki M; Ohyama C
    Urol Oncol; 2022 Feb; 40(2):64.e1-64.e8. PubMed ID: 34973857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases.
    Myint ZW; El Khouli R; Lemieux B; Yan D; St Clair WH; Liu X; Kunos CA
    BMC Cancer; 2022 Apr; 22(1):415. PubMed ID: 35428207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort.
    Rathbun JT; Franklin GE
    Curr Probl Cancer; 2019 Jun; 43(3):205-212. PubMed ID: 29983206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
    Winter BM; von Rundstedt FC; Grimm MO
    Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
    Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.
    Kim JW; Shin MS; Kang Y; Kang I; Petrylak DP
    Clin Genitourin Cancer; 2018 Apr; 16(2):e469-e476. PubMed ID: 29137877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.
    Zhang I; Gilbo P; Kohn N; Cox B
    Pract Radiat Oncol; 2018; 8(6):452-457. PubMed ID: 29934137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
    Fizazi K; Scher HI; Miller K; Basch E; Sternberg CN; Cella D; Forer D; Hirmand M; de Bono JS
    Lancet Oncol; 2014 Sep; 15(10):1147-56. PubMed ID: 25104109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies.
    Dan TD; Eldredge-Hindy HB; Hoffman-Censits J; Lin J; Kelly WK; Gomella LG; Lallas CD; Trabulsi EJ; Hurwitz MD; Dicker AP; Den RB
    Am J Clin Oncol; 2017 Aug; 40(4):342-347. PubMed ID: 25723740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.
    Parimi S; Bondy S; Tsang E; McKenzie MR; Bachand F; Aparicio M; Duncan G; Sunderland K; Olson RA; Pai HH; Alexander AS; LaPointe V; Chi KN; Tyldesley S
    Can Urol Assoc J; 2019 Oct; 13(10):E311-E316. PubMed ID: 31364977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer.
    Agarwal N; Nussenzveig R; Hahn AW; Hoffman JM; Morton K; Gupta S; Batten J; Thorley J; Hawks J; Santos VS; Nachaegari G; Wang X; Boucher K; Haaland B; Maughan BL
    Clin Cancer Res; 2020 May; 26(9):2104-2110. PubMed ID: 31937614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.